NCT07849777Not yet recruiting
Early Anticoagulation Therapy After Endovascular Treatment for Acute Ischemic Stroke With Atrial Fibrillation
Source: ClinicalTrials.gov · Last updated 15 Oct 2026
Brief summary (registry, in English)
The goal of this clinical trial is to learn whether starting a direct oral anticoagulant (DOAC) early after endovascular treatment works to improve outcomes in patients with ischemic stroke related to atrial fibrillation. It will also learn about the safety of early DOAC treatment. The main question it aims to answer is: \- Does starting DOAC treatment 24 hours after endovascular treatment improve outcomes at 3 months compared with starting it 5 days after randomization? Researchers will compare early DOAC treatment (started 24 hours after the procedure) with delayed DOAC treatment (started 5 days after randomization) to see if early treatment works better. Participants will: * Have atrial fibrillation-related acute ischemic stroke caused by a large vessel blockage in the front part of the brain, within 24 hours of symptom onset * Be randomly assigned to one of two groups after endovascular treatment: early DOAC treatment or delayed DOAC treatment * Take DOACs starting 24 hours after the procedure (early group) or 5 days after randomization (delayed group) * Be followed up for 3 months to check their recovery and any medical problems
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 474 (estimated)
- First submitted
- 21 Sept 2026
- Start date
- 30 Sept 2026
- Primary completion date
- 30 Sept 2029
- Lead sponsor
- The Fourth Affiliated Hospital of Soochow University
- Diseases
- Stroke, Atrial fibrillation
- NCT number
- NCT07849777
What you commit to
- Study type: Interventional
- Planned participants: 474
- From 30 Sept 2026 to the primary completion date, 30 Sept 2029
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concomitant use of azole antifungal agents, HIV protease inhibitors, or strong CYP3A4 inducers.
- History of major trauma or major surgery within 1 month before stroke onset.
- Evidence of active bleeding within 1 month before stroke onset, including but not limited to gastrointestinal bleeding or genitourinary bleeding.
- Participation in another interventional clinical trial within the previous 3 months.
Other illness
- Pre-stroke modified Rankin Scale (mRS) score \>2.
- Known hypersensitivity to anticoagulants or any other contraindication to anticoagulant therapy.
- Any terminal illness with an expected life expectancy of less than 6 months.
- Any other condition that, in the investigator's judgment, would make the participant unsuitable for the study or interfere with study participation or completion, including but not limited to psychiatric disorders, cognitive or emotional impairment, or physical conditions that preclude adherence to study procedures or follow-up.
Lab values
- Presence of systemic bleeding disorders, coagulopathy, or a platelet count \<100 × 10⁹/L.
- Severe hepatic or renal impairment, or receipt of dialysis for any cause. Severe hepatic impairment is defined as alanine aminotransferase (ALT) \>3 times the upper limit of normal (ULN) or aspartate aminotransferase (AST) \>3× ULN. Severe renal impairment is defined as serum creatinine \>3.0 mg/dL (265.2 μmol/L) or an estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m².
Other
- Valvular atrial fibrillation.
- Presence of intracranial space-occupying lesions, including intracranial tumors or cerebral vascular malformations.
- Cerebral amyloid angiopathy.
- Breastfeeding women.
Who the study is looking for
- Age ≥18 years.
- Symptom onset within 24 hours before enrollment.
- A confirmed diagnosis of acute anterior circulation ischemic stroke.
- A baseline NIHSS score ≥6 at admission.
- An Alberta Stroke Program Early CT Score (ASPECTS) ≥6.
- Computed tomography angiography (CTA), magnetic resonance angiography (MRA), or digital subtraction angiography (DSA) confirming occlusion of the intracranial internal carotid artery (ICA) or the M1/M2 segment of the middle cerebral artery (MCA), with the patient scheduled to undergo EVT.
- Computed tomography (CT) or magnetic resonance imaging (MRI) performed within 24 hours after EVT demonstrating no evidence of hemorrhagic transformation.
- Documentation of paroxysmal, persistent, or permanent atrial fibrillation based on electrocardiography or previous medical records.
- Written informed consent provided by the patient or a legally authorized representative.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Neurology, Huashan Hospital, Fudan University Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
| The Fourth Affiliated Hospital of Soochow University Coordinator of this site? Confirm its status | Suzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.